Inc.'s (MRK - Analyst Report) on the approval of Merck's Noxafil injection in the U.S. The new formulation of Noxafil, which uses Ligand Pharma's Captisol technology, is approved for the prevention of invasive aspergillus and candida infections in ...
Ligand Pharmaceuticals Inc (LGND): LGND stock is down 1.7%, marking the third consecutive day the stock has decreased. For more information on the best stocks to buy right now, check out the latest commentary on InvestorPlace.
The company had attracted high profile institutional investors, had leveraged technology capable of transforming our understanding of immunotherapy, and was riding the momentum of having entered into partnership with Intrexon (XON).
Pharmaceutical Online (press release) - Mar 19, 2014
Ligand is partnered with global pharmaceutical leaders including GlaxoSmithKline, Onyx Pharmaceuticals (a subsidiary of Amgen Inc.), Baxter International, Eli Lilly & Co., Spectrum Pharmaceuticals in addition to the above-mentioned Pfizer and Merck.